Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.


Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Innovation at Syngene: Translatable models for improving cancer research
Syngene scientists have developed orthotopic and spheroid tumor models, which can help improve translatability and clinical relevance for cancer research.
12th Jun, 2024
pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs
Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.
28th Nov, 2023
Leveraging High Throughput Screening services to accelerate drug discovery and development
The many applications of HTS and how it has evolved beyond lead identification and candidate optimization today.
18th Aug, 2023
Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer
How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.
19th Jun, 2023
Five questions that determine the success of your PROTAC programs
Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.
18th Oct, 2022
Solving problems with science: Gene to GMP-grade clinical supply in nine months
How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.
6th Sep, 2022
Minimizing environmental footprint the Syngene way
How Syngene is driving behavioural change in responsible use of natural resources while researching new technology and opportunities to improve its sustainability performance continuously.
24th Jun, 2022
Driving operational excellence with SQDECC
SQDECC is an industry-recognized model that enables the operational teams to get a unified view of their efficiency across parameters of Safety, Quality, Delivery, Engagement, Cost, and Compliance (SQDECC).
3rd Dec, 2021
How Organocatalysis discovered by Nobel laureates revolutionised drug development and production in Syngene
11th Oct, 2021
Design of Experiment (DoE) - An efficient tool for process optimization
DoE is achieving increasing acceptance in the pharmaceutical sector as it is being seen as an efficient tool for process optimization, including helping to develop quality products.
31st May, 2021

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details